Christophe Willekens, MD

Articles by Christophe Willekens, MD

Dr. Willekens Presents Efficacy Findings for Reduced-Dose Venetoclax in AML

Christophe Willekens, MDAcute Myeloid Leukemia | July 16, 2024

Christophe Willekens, MD, compares standard dosing venetoclax for AML to seven-day dosing plus azacitidine.